Generic Injectable Market (By Product Type: Chemotherapy agents, Small molecule antibiotics, Vaccines, Peptide antibiotics, Blood factors, Peptide hormone, Insulin, Cytokines, Immunoglobin, Monoclonal Antibodies; By Molecular Type: Small Molecule, Large Molecule; By Application; By Administration; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

According to Nova one advisor, the global Generic Injectable Market Size was valued at USD 95.3 billion in 2022 and is predicted to be worth USD 340.1 billion by 2032, with a CAGR of 15.58% from 2023 to 2032. 

Key Takeaway:

• The large molecule type segment has held 70% revenue share in 2022.
• The small molecule segment accounted 32% market share in 2022.
• North America region has dominated the market with revenue share of around 47% in 2022.

Generic Injectables Market: Overview

• This report analyzes the current scenario and future prospects of the global generic injectables market. Rise in prevalence of various diseases such as cancer, diabetes, and cardiac across the world, increase in demand for generic injectables, and surge in the geriatric patient pool are the key factors projected to drive the global generic injectables market during the forecast period.
• The report provides an elaborate executive summary, including a snapshot of various segments of the global generic injectables market. It also provides elaborate information and data analysis of the global generic injectables market about segments based on product type, application, container type, route of administration, and region.
• The overview section of the report provides a detailed qualitative analysis of drivers and restraints, and opportunities that impact the global generic injectables market
• Additionally, the report includes company profiles which provide information about their business, product portfolios, and competitive landscape in the global generic injectables market
• The report on the global generic injectables market offers market attractiveness analysis of the regions and segments
• The last section of the report comprises quantitative and qualitative analysis on market share/position of key players operating in the global generic injectables market. It analyzes the key competitive strategies adopted by the major industry players, thereby presenting a thorough understanding of the competitive scenario in the global generic injectables market.

Report Scope of the Generic Injectable Market

Challenges Posed by Syringe Inspection Affect Market Growth

Syringes are among the most difficult containers to inspect. With the largest vaccination effort in human history, challenges posed by syringe inspection become especially relevant while considering the ever-growing adoption of injectable drugs. These findings have led to the need of sophisticated inspection systems to help manufacturers address not only the coronavirus pandemic but also various other maladies.

While other containers such as cartridges, vials, and ampoules largely stand still and can enter the inspection process independently, syringes are typically carried via conveyor and then turned upside down. This has resulted in the need for robust inspection systems so that any hidden particles in the funnel can sink down into the liquid for increased inspection detectability.

Manufacturers Expand Revenue Streams in Routine, Complex Injectable Products

The global generic injectables market is projected to clock a CAGR of 15.58% during the forecast period. Biological E Limited - an Indian biotechnology and biopharmaceutical company based in Hyderabad, Telangana, is gaining recognition for broadening its portfolio in 20 routine and complex injectable products. In order to establish stable revenue streams, companies are tapping into regulated markets and exploring other markets to generate income sources.

There is a growing demand for specialty generic injectables packaged in glass vials. Express Pharma in associated with West Pharma recently conducted a webinar to understand why emerging generic injectable manufacturers need flexibility and simplicity when dealing with drug delivery and containment.

Product Type Insight

Monoclonal antibodies to hold the highest market share with increased revenue during the forecast period of generic injectables.

Molecule Type Insight

Increased research and development in large molecules for developing the generic injectables with increased opportunity and increased share in the market.

Which helps to increase the market of generic injectables. However, the small molecule segment is poised to grow at a higher CAGR during the forecast period 2023 to 2032.

Application Insight

Increased growth of the diabetes disease with increased life style and dietary supplements with high rate of patients among the population due to the previous family or increased obesity. Which led to increase of the diabetes with increased demand for the generic injectables. Oncology is also rising from the year 2021 with increased chemotherapies and generic injectables with high demand for the medication from the health care centre. However, the diabetes segment is growing at the strongest CAGR from 2023 to 2032.

Distribution Channel Insight

Segmentation of generic injectables based on distribution channel involves Hospital pharmacy, retail pharmacy, drug stores and online pharmacy. Due to increased chronic infectious diseases with enlargement of the hospitals with their own hospital pharmacy increase growth of the hospital across the regions. Hospital pharmacy to hold the largest market.

Generic Injectables Market: Regional

Segmentation of generic injectables based on geography sector North America to be the leading region with highest market growth of the generic injectables with increased development of the generic injectables with increased research and development from the key market players for introducing the generic injectables with increased demand from the health care center due to shortage of the injectable with increased chronic infectious diseases among the population with increased hospitalization rate of the patients.

Asia pacific region also helps to boost the market growth with increased demand from the health care centre for generic injectables with increased chronic diseases increasing due to rising population. Other regions such as Europe, Latin America, Middle East and Africa contributes to increase the market of generic injectables to a larger extend.

Recent Developments

• Prochlorperazine Edisylate drug infusion a drug from the Cosette Pharmaceutical Inc, which is identical drug to another drug such as Compazine injection 10mg/2ml. Prochlorperazine Edisyalte is utilised to manage the queasiness and retching. Prochlorperazine is also utilized in controlling schizoprenia.
• In the year 2022 March, Collaboration of Midatech Pharma and Johnson & Johnsons Pharmaceuticals in the year 2020 July. Increased drug delivery technology with the aim of bio delivery increased research and development in biodistribution.
• In the year 2022 January, Hikma Pharmaceutical for US introduced the new 503B, a new sterile drug with increased business with increased effectivity, quality, injectables, and other increased medications.

Some of the prominent players in the Generic Injectable Market include:

• DR. Reddys Laboratries Ltd
• Baxter International
• Mylan N.A
• Teva Pharmaceuticals
• Astra Zeneca Plc
• Sanofi S.A
• Fresenius Kabi
• Pfizer Inc
• Cipla Ltd
• Merck & Co. Inc
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Aurobindo Pharma Limited
• Samsung Biologics Co Ltd
• Biocon
• Lupin,Ltd
• Astrazeneca
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals
• Cosette Pharmaceutical, Inc
• Johnson & Johnson Services, Inc
• Sanofi SA
• Amgen Inc.
• Bristol- Myers Squibb Company
• Piramal Pharma Solutions
• Merck KGaA

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Generic Injectable market.

By Product Type

• Chemotherapy agents 
• Small molecule antibiotics 
• Vaccines 
• Peptide antibiotics 
• Blood factors 
• Peptide hormone 
• Insulin 
• Cytokines 
• Immunoglobin 
• Monoclonal Antibodies

By Molecular Type

• Small Molecule
• Large Molecule

By Application

• Oncology
• Diabetes 
• Infectious Diseases 
• Blood Disorders 
• Musculoskeletal Disorders 
• Hormonal Disorders 
• Pain Management 
• CNS Diseases 
• Cardiovascular Diseases

By Administration

• Intravenous (IV)
• Intramuscular (IM)
• Subcutaneous (SC)

By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Drug stores
• Online pharmacy

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Generic Injectable industry analysis from 2023 to 2032 to identify the prevailing Generic Injectable industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Generic Injectable industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Generic Injectable industry trends, key players, market segments, application areas, and market growth strategies.